OncoMatch

OncoMatch/Clinical Trials/NCT03498326

Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer

Is NCT03498326 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Gemcitabine and Gemcitabine for pancreatic cancer.

Phase 2RecruitingSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT03498326Data as of May 2026

Treatment: Gemcitabine · GemcitabineThe prognosis of pancreatic cancer is extremely poor, even in those patients who had underwent surgery, the 5-year survival is still less than 10%. Current guidelines recommend Gemcitabine monotherapy for R0 resection of pancreatic cancer. Inflammation plays an critical role in the development and progression of pancreatic cancer. Here we intend to assess the synergistic effect of using celecoxib in combination with gemcitabine on the treatment of R0 resection of pancreatic cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: surgery — R0 resection

Surgery for R0 resection

Cannot have received: gemcitabine chemotherapy (gemcitabine)

The gemcitabine chemotherapy regimen was not previously used for the treatment of other malignancies

Cannot have received: radiation therapy

Pancreatic cancer received radiotherapy before surgery

Lab requirements

Blood counts

neutrophil count is at least 1.5*10^9/ml, platelet count is at least 100*10^9/ml, hemoglobin is at least 80g/L

Kidney function

creatinine ≤ 1.2 mg/dL

Liver function

bilirubin does not exceed 1.5 times the upper limit of normal; alanine aminotransferase and aspartate aminotransferase does not exceed the upper limit of normal 3 times

Blood routine: The neutrophil count is at least 1.5*10^9/ml, and the platelet count is at least 100*10^9/ml.Hemoglobin is at least 80g/L. Liver function: bilirubin does not exceed 1.5 times the upper limit of normal; alanine aminotransferase and aspartate aminotransferase does not exceed the upper limit of normal 3 times; kidney function: creatinine ≤ 1.2 mg/dL.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify